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Beneficial impact on cardiovascular risk factors by dual block-
ade of the rennin-angiotensin system in diabetic nephropathy.
Background. Patients with diabetic nephropathy have a high
risk of cardiovascular disease and end-stage renal disease. Dual
blockade of the renin-angiotensin system (RAS) with both ACE
inhibitors (ACE-I) and angiotensin II receptor blockers may
offer therapeutic advantages.
Methods. Based on three double-blind randomized cross-
over trials, we analyzed the short-term effects of dual blockade
of the RAS on cardiovascular surrogate end points in 51 type 1
diabetic patients with diabetic nephropathy.
Results. Compared to ACE-I, dual blockade of the RAS de-
creased albuminuria 37% from 558 mg/24 hour, and lowered 24-
hour blood pressure 7/5 mm Hg from 137/76 mm Hg (P < 0.01).
In addition, dual blockade lowered total and LDL-cholesterol
0.3 from 5.4 mmol/L and 3.1 mmol/L, respectively (P ≤ 0.01).
The antialbuminuric response to dual blockade of the RAS was
influenced by the insertion (I)/deletion (D) polymorphism in
the ACE gene.
Conclusion. Dual blockade of the RAS may offer additional
cardiovascular and renal protection in type 1 diabetic patients
with diabetic nephropathy. Determination of the ACE/ID geno-
type may help identify patients particularly sensitive to such
therapy.
Diabetic nephropathy develops in approximately 40%
of all patients with diabetes mellitus, and has become
the leading cause of end-stage renal disease in Europe,
Japan, and the United States, accounting for 25% to
42% of all cases. Because renoprotective therapy has im-
proved renal survival and prognosis, more patients will
develop cardiovascular events [1]. Consequently, addi-
tional treatment strategies focusing on cardiovascular
diseases should be considered in patients with diabetic
nephropathy. Blockade of the renin-angiotensin system
(RAS) with ACE inhibitors (ACE-I) in type 1 diabetic
patients with diabetic nephropathy [2–5], and with an-
giotensin II receptor blockers (ARB) in type 2 diabetic
patients with elevated urinary albumin excretion [4–8]
are the first line therapy for kidney protection. Due to
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the different mechanisms of action of ACE-I and ARB,
simultaneous treatment with both compounds may offer
synergistic blockade of the RAS, not obtainable with ei-
ther drug alone. The CHARM-added trial [9], performed
in patients with chronic heart failure, and The COOPER-
ATE trial [10] in patients with nondiabetic renal disease
have demonstrated superior effects of dual blockade of
the RAS on primary end points when compared to treat-
ment with either ACE-I or ARB. On the contrary, in the
VALIANT trial [11], dual blockade of the RAS did not
improve survival in patients with acute heart failure after
myocardial infarction.
METHODS
In this paper, we present data dealing with the short-
term effects of dual blockade of the RAS on cardiovas-
cular risk factors in 51 type 1 diabetic patients with dia-
betic nephropathy compared to ACE-I treatment alone.
In addition, we focus on which parameters predict the
individual response to dual blockade of the RAS. The
analysis includes all patients participating in three ran-
domized, double-blind, cross-over trials of the short-term
effects of dual blockade of the RAS [12–14]. All patients
received both dual blockade of the RAS using ARB (irbe-
sartan 300 mg [12, 14] or valsartan 80 mg [13]) in combi-
nation with ACE-I (captopril 100 mg or enalapril 20 mg,
or benazepril 20 mg [12, 13] or enalapril 40 mg [14]) and
monotherapy with the same ACE-I. Each treatment pe-
riod lasted eight weeks. At the end of each treatment
period the cardiovascular risk profile, including albumin-
uria, 24-hour blood pressure, lipids, metabolic control,
and others, were determined. In this analysis, we com-
pared risk factors on dual blockade therapy versus on
ACE-I therapy alone. Type 1 diabetes mellitus was diag-
nosed according to WHO criteria, and diabetic nephropa-
thy was defined as persistent albuminuria >300 mg/24 h
(>200 lg/min) in two out of three consecutive determi-
nations, presence of diabetic retinopathy, and no other
kidney or renal tract disease [13]. Patients were all Cau-
casians, 43 (SD 9) years of age, and 37 were men.
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Table 1. Cardiovascular effects of dual blockade of the renin angiotensin system compared to ACE-I treatment in 51 type 1 patients with diabetic
nephropathy
Monotherapy Dual blockade Mean
with ACE-I of the RAS difference (95%CI) P value
Albuminuria mg/24 houra 558 (392,794) 349 (233,524) −37% (−47,−26) <0.0001
Glomerular filtration rate mL/min/1.73m2 67 (4) 64 (4) −4 (−6,−1) 0.0064
24-hour systolic blood pressure mm Hg 137 (2) 129 (2) −7 (−11,−3) 0.0007
24-hour diastolic blood pressure mm Hg 76 (1) 71 (1) −5 (−7,−3) <0.0001
Plasma cholesterol mmol/L 5.4 (0.2) 5.1 (0.1) −0.3 (−0.6, −0.1) 0.0139
Plasma LDL mmol/L 3.1 (0.1) 2.8 (0.1) −0.3 (−0.5, −0.1) 0.0095
Plasma HDL mmol/L 1.6 (0.1) 1.6 (0.1) 0.0 (0.0, 0.1) 0.3811
Plasma potassium mmol/L 4.1 (0.1) 4.4 (0.1) 0.3 (0.2,0.4) <0.0001
Hemoglobin mmol/L 8.0 (0.1) 7.6 (0.1) −0.4 (−0.5,−0.3) <0.0001
Hemoglobin A1c % 9.4 (0.2) 9.6 (0.2) 0.2 (0.0,0.4) 0.0607
Values represented are mean (SEM).
aGeometric mean (95%CI).
RESULTS AND DISCUSSION
Treatment effects of eight weeks of dual blockade of
the RAS compared to ACE-I alone are summarized in
Table 1.
A large interindividual variation in the response to
dual blockade was seen. The antialbuminuric response
to dual blockade of the RAS was influenced by the inser-
tion (I)/deletion (D) polymorphism in the gene coding for
angiotensin-converting enzyme (ACE/ID). Patients car-
rying the D allele had a significant poorer response [mean
31% (95% CI 16 to 43)] compared to patients with the II
genotype [55% (35 to 69)], P = 0.021. This observation
is in concord with earlier findings in type 1 diabetic pa-
tients with diabetic nephropathy treated with ACE-I [15,
16], but in contrast to studies using ARB [17, 18]. The
only parameter predicting an enhanced antihypertensive
effect of dual blockade in the present study was a high sys-
tolic blood pressure on ACE-I alone. If confirmed, these
findings may help identify patients who could benefit the
most from dual blockade therapy.
Exclusion criteria at entry in our studies were plasma
potassium >4.8 mmol/L and glomerular filtration rate
<30 mL/min/1.73m2 [12–14]. We observed a statistical
significant, but reversible, decline in glomerular filtration
rate (GFR) of 4 mL/min/1.73m2 as response to dual block-
ade therapy. An initial decline in GFR when blocking the
RAS is a well described phenomenon [19], and a large
decline has been suggested to predict a subsequent more
stable renal function in diabetic and nondiabetic renal
disease [19, 20]. Dual blockade therapy was found to be
safe and well tolerated if plasma potassium are monitored
after initiation of therapy. In agreement, in high-risk pa-
tients with heart failure, dual blockade treatment caused
hypotension in 5% of patients, hyperkalemia in 3%, and
increase in creatinine in 8% of patients [9].
The demonstration of a lipid-lowering effect of dual
blockade in the present study is in agreement with recent
findings in nondiabetic renal disease, suggesting a dose-
dependent effect of ACE-I (lisinopril up to 40 mg daily)
on serum lipids [21]. The decrease in plasma total and
LDL cholesterol are likely to be related to the antialbu-
minuric effect of aggressive RAS blockade, which further
emphasizes the importance of reduction of albuminuria
in patients with kidney diseases.
Blood pressure, albuminuria, plasma cholesterol, and
LDL-cholesterol are established surrogate end points for
long-term cardiovascular outcome in diabetic patients.
Consequently, in addition to renal preservation, dual
blockade of the RAS may offer cardiovascular protection
in these patients. However, long-term studies evaluating
primary end points are needed to establish the effects
of this new treatment strategy in type 1 diabetic patients
with diabetic nephropathy.
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